Lataa...
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
PURPOSE: To review published evidence for a treatment interval extension to ≥12-weeks in neovascular macular degeneration treated with intravitreal Aflibercept. METHODS: A systematic search was performed in the NCBI/PubMed database to identify pro- and retrospective studies retrieved by the key term...
Tallennettuna:
| Julkaisussa: | Clin Ophthalmol |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6650619/ https://ncbi.nlm.nih.gov/pubmed/31409968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S185756 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|